Table 1.
Characteristic | No. of Patients (n = 100) | |
---|---|---|
Age, years | ||
Median | 17 | |
Range | ≤ 1-82 | |
Sex | ||
Male | 63 | |
Female | 37 | |
Diagnosis | ||
Osteosarcoma | 42 | |
Other | 58 | |
Thymidine administration | ||
No | 56 | |
Yes | 44 | |
MTX dose, g/m2 | ||
Median | 7.7 | |
Range | 0.4-12 | |
Infusion duration, hours | ||
Median | 4 | |
Range | 1-36 | |
Plasma MTX at 36-48 hours, μM | ||
< 50 | 45 | |
≥ 50 | 52 | |
Unavailable | 3 | |
Plasma MTX prior to glucarpidase, μM | ||
Median | 17 | |
Range | 0.37-849 | |
Serum creatinine, mg/dL | ||
Median | 3.1 | |
Range | 0.8-10.2 | |
Diuretic use | ||
No | 19 | |
Yes | 65 | |
Unavailable | 16 | |
Dialysis use | ||
No | 67 | |
Yes | 27 | |
Unavailable | 6 | |
Appropriate leucovorin increase* | ||
No | 12 | |
Yes | 86 | |
Unavailable | 2 | |
Grade 4 toxicity† prior to glucarpidase | ||
No | 81 | |
Yes | 14 | |
Unavailable | 5 | |
Glucarpidase doses | ||
1 | 62 | |
2 every 24 hours | 27 | |
3 every 4 hours | 5 | |
Delayed dose | 6 | |
Initial plus delayed glucarpidase dose (hours after start of MTX) | ||
≤ 96 | 71 | |
> 96 | 27 | |
Unavailable | 2 |
Abbreviation: MTX, methotrexate.
Increased leucovorin dose to 100-1,000 mg/m2 every 3 to 6 hours within 3 days of the start of the MTX infusion.
Grade 4 toxicity defined as mucositis, neutropenia, febrile neutropenia/sepsis, skin toxicity, diarrhea, and nausea/vomiting.